美宝Mebo品牌怎么样 申请店铺

我要投票 美宝Mebo在医疗器械行业中的票数:529 更新时间:2025-07-24
美宝Mebo是哪个国家的品牌?「美宝Mebo」是 美宝医药科技集团有限公司 旗下著名品牌。该品牌发源于广东省汕头市,由创始人杨智斌在1990-08-06期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力美宝Mebo品牌出海!将品牌入驻外推网,定制美宝Mebo品牌推广信息,可以显著提高美宝Mebo产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

美宝Mebo怎么样

成立于1987年,伤药知名品牌,其湿润烧伤膏为原位皮肤再生治疗烧伤的知名药品,主要从事烧伤、创疡、皮肤再生医药医疗的企业


美宝集团,是惠及世界的新生命科学企业集团,拥有丰富的世界化的知识产权财富,是世界烧伤创疡再生医疗技术MEBO/MEBT奠基地,是实现美国总统“发展药物使损伤器官再生”国策的经济领航体,是再生生命产业链引擎,是人类进入再生生命新经济世界的引导型企业。

美宝集团成立于1987年,前身是徐荣祥医生和李俐医生创建的北京光明中医烧伤创疡研究所。1988年,徐荣祥发明的湿润烧伤膏获得中国卫生部新药证书,成为1984年中国《药品管理法》实施后被批准的中药新药。该药物与烧伤湿润暴露疗法(MEBT/MEBO)是八五规划中卫生部向全国推广普及的十项医药技术之一。

美宝集团在中国、美国分设两个总部,拥有美国、中国、泰国、印度、马来西亚等多家跨国的烧伤、创疡、皮肤再生医药医疗企业,拥有具有自主知识产权的药品、保健品、营养食品、美容护肤产品、医疗器械等几十余种系列再生产品。在70多个国家,有20多万医生在20多个领域使用美宝的技术及产品,治愈了4000多万烧伤创疡患者,实现了大面积深度烧伤、糖尿病溃疡、末节断指、开放缺损型创伤、下肢溃疡、深度褥疮等损伤器官的原位再生复原。

美宝集团拥有40多项中、美、欧、日等国家和地区的国际发明专利,包括潜能再生细胞及其培养方法、通过体内和原位进行干细胞的培养来修复再生生理性的组织和功能性的器官等核心器官再生专利。美宝创始人徐荣祥所著《人体再生复原科学》、《烧伤再生医学与疗法》、《烧伤医疗技术蓝皮书》及《烧伤治疗大全》均被美国国家医学图书馆收录;而由瑞士Karger出版社出版的英文版《烧伤再生医学与疗法》(Burns Regenerative Medicine and Therapy)一书被哈佛大学、普林斯顿大学、麻省理工学院等十几所大学收藏。

美宝拥有国际化的基础和临床研究中心,有北京美宝烧伤创疡研究所、北京荣祥再生医学研究所,美国临床研究中心等多处研究基地。在创始人徐荣祥医生过世后,新任董事局主席徐鹏带领美宝拓展了一系列国际科研、企业与社会平台:加入了克林顿全球倡议并实施了惠及20,000名中国医生的美宝倡议“再生医疗技术医师培训”;加入了联合国“每个妇女、每个儿童”中国合作伙伴网络;与美国洛杉矶郡卫生局合作在洛杉矶卫生系统筹划“再生医疗技术培训”;在哈佛大学医学院合作建立了“徐荣祥再生治疗中心”;在南加州大学戴维斯老年学院合作成立了“徐荣祥再生生命科学中心”;冠名成立了洛杉矶州大“徐荣祥健康与公众服务大学”及“徐荣祥生物科学创新中心”等。美宝开始多方面多层次开展国际合作,进行人体损伤器官的再生复原研究、临床推广应用以及再生科学人才与社会领袖的培养。与此同时,还发起了美国徐荣祥基金会,中国红基会徐荣祥再生生命公益基金,通过另一种渠道在维护国际健康事务中积极发挥重要作用。

美宝不仅是一个公司,更是一个”为人类生命奋斗“的使命型企业,是一个为人类造福的科学技术集群。创始人徐荣祥在世界烧伤治疗领域和再生科学领域对人类社会做出了历史性贡献,为人类损伤器官再生的广泛临床应用奠定了坚实的基础,并为世界再生生命科学的发展提供了新的方向。


Founded in 1987, it is a well-known brand of wound medicine. Its MEBO is a well-known medicine for in-situ skin regeneration treatment. It is mainly engaged in burn, wound and skin regeneration medicine and medical treatment. It is a new life science enterprise group benefiting the world. It has rich world-wide intellectual property wealth. It is the foundation of MEBO / MEBT, a world burn regeneration medical technology The economic leader of the current US president's national policy of "developing drugs to regenerate damaged organs" is the engine of the industrial chain of renewable life and the leading enterprise for human beings to enter the new economic world of renewable life. Meibao group was founded in 1987, formerly known as Beijing Guangming burn and wound research institute founded by Dr. Xu Rongxiang and Dr. Li Li. In 1988, the MEBO invented by Xu Rongxiang obtained the new drug certificate issued by the Ministry of health of China and became a new Chinese medicine approved after the implementation of the drug administration law of China in 1984. MEBT / MEBO is one of the ten medical technologies popularized by the Ministry of health in the eighth five year plan. Meibao group has two headquarters in China and the United States. It has many multinational burn, wound and skin regeneration pharmaceutical and medical enterprises in the United States, China, Thailand, India, Malaysia, etc. it has more than ten series of renewable products, such as drugs, health products, nutritional food, beauty and skin care products, medical devices, etc. with independent intellectual property rights. In more than 70 countries, more than 200000 doctors have used Meibao's technology and products in more than 20 fields, cured more than 40 million patients with burns, wounds and ulcers, and realized in-situ regeneration and recovery of large-scale deep burns, diabetic ulcers, end segment severed fingers, open defect wounds, lower limb ulcers, deep bedsores and other damaged organs. Meibao group has more than 40 international invention patents in China, the United States, Europe, Japan and other countries and regions, including potential regenerative cells and their culture methods, core organ regeneration patents such as repairing physiological tissues and functional organs through stem cell culture in vivo and in situ. The science of human regeneration and recovery, burn regeneration medicine and therapy, blue book of burn medical technology and burn treatment encyclopedia, written by Xu Rongxiang, the founder of Meibao, are all included in the National Medical Library of the United States, while the English version of Burns Regenerative Medicine and therapy, published by Karger press in Switzerland, is published by Harvard University and general public Linton University, Massachusetts Institute of technology and more than a dozen universities. Meibao has international basic and clinical research centers, including Beijing Meibao burn and wound Research Institute, Beijing Rongxiang Regenerative Medicine Research Institute, American clinical research center and other research bases. After the death of Dr. Xu Rongxiang, the founder, Xu Peng, the new chairman of the board of directors, led Meibao to expand a series of international scientific research, enterprise and social platforms: joined the Clinton Global Initiative and implemented the benefit 20, MEBO initiative "training of regenerative medical technologists" of 000 Chinese doctors; joining the "every woman, every child" Chinese partner network of the United Nations; planning "regenerative medical technology training" in Los Angeles health system in cooperation with Los Angeles County Health Bureau of the United States; establishing "Xu Rongxiang regenerative treatment center" in Harvard University School of medicine; David, University of Southern California The Institute has established "Xu Rongxiang renewable Life Science Center" in cooperation, and "Xu Rongxiang health and public service university" and "Xu Rongxiang biological science innovation center" in Los Angeles State University. Meibao began to carry out international cooperation in various aspects and at various levels to carry out research on the regeneration and restoration of human damaged organs, clinical promotion and application, and training of regeneration science talents and social leaders. At the same time, it also launched the American Xu Rongxiang foundation and the Chinese Red foundation Xu Rongxiang renewable life public welfare fund, which play an important role in maintaining international health affairs through another channel. Meibao is not only a company, but also a mission enterprise "striving for human life". It is a scientific and technological cluster for the benefit of mankind. Xu Rongxiang, the founder, has made historic contributions to human society in the field of burn treatment and regeneration Science in the world, laying a solid foundation for the extensive clinical application of human organ regeneration, and providing a new direction for the development of world regeneration life science.

本文链接: https://brand.waitui.com/47c9dcac4.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

A股三大指数午间休盘集体上涨,雅江电站概念持续爆发

36氪获悉,A股三大指数午间休盘集体上涨,沪指涨0.48%,深成指涨0.65%,创业板指涨0.72%;雅江电站概念持续爆发,中国电建4连板,山河智能、西藏天路涨停;海南自贸港、稀土概念走强,海南机场、海南发展、包钢股份涨停,北方稀土涨超5%;光模块、贵金属板块跌幅居前,太辰光跌超8%,中金黄金、天孚通信跌超4%。

2小时前

哥大同意支付逾2亿美元与美国政府达成和解

美国哥伦比亚大学23日发表声明说,已与联邦政府达成协议,将支付逾2亿美元和解金,以恢复联邦政府对该校的科研经费支持。哥伦比亚大学代理校长克莱尔·希普曼在声明中说,这一协议标志着在经历一段持续联邦审查和不确定性后的重要进展。和解协议经过精心设计,旨在保护哥大核心价值观,并使哥大与联邦政府之间至关重要的科研合作得以重回正轨。(新华社)

2小时前

阿里速卖通:潜水面罩商家Darek3个月热卖10万单

36氪获悉,阿里速卖通数据显示,潜水面罩商家Darek在今年6-8月欧洲及韩国市场热销超10万单。据了解,除了持续在速卖通欧洲以及韩国流向仓充分备货之外,Darek结合AliExpress NN频道优化产品组合,也成了爆单的重要手段之一。该频道显著提升转化并提供补贴,其一款爆品7月环比增长达150%。

2小时前

中慧生物向港交所提交上市申请

36氪获悉,据港交所文件,江苏中慧元通生物科技股份有限公司-B向港交所提交上市申请书,联席保荐人为中信证券、招银国际。

2小时前

立讯精密增资至72.47亿元

36氪获悉,爱企查App显示,近日,立讯精密工业股份有限公司发生工商变更,注册资本由约71.79亿元人民币增至约72.47亿元人民币。立讯精密工业股份有限公司成立于2004年5月,法定代表人为王来春,经营范围为生产经营连接线、连接器、电脑周边设备、塑胶五金制品。股东信息显示,该公司由立讯有限公司、香港中央结算有限公司等共同持股。

2小时前

本页详细列出关于美宝Mebo的品牌信息,含品牌所属公司介绍,美宝Mebo所处行业的品牌地位及优势。
咨询